Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Current Signal: BUY (auto-tracking)
2.84% $308.59
America/New_York / 26 apr 2024 @ 12:29
FUNDAMENTALS | |
---|---|
MarketCap: | 25 457 mill |
EPS: | 8.25 |
P/E: | 37.40 |
Earnings Date: | Jul 23, 2024 |
SharesOutstanding: | 82.50 mill |
Avg Daily Volume: | 0.556 mill |
RATING 2024-04-26 |
---|
A+ |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Buy | |
Return On Asset: | Buy | |
DE: | Buy | |
P/E: | Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 37.40 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
2.00x |
Company: PE 37.40 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
$667.51 (116.31%) $358.92 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 302.04 - 318.30 ( +/- 2.62%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $308.59 (2.84% ) |
Volume | 0.300 mill |
Avg. Vol. | 0.556 mill |
% of Avg. Vol | 53.86 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $273.25 | N/A | Active |
---|
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.